United Therapeutics Corporation, Research Triangle Park (United States of America)
Follow
Contributor content
Presentation
Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review
